Challenges in Delivering Most-Favored-Nation Pricing for Prescription Drugs in the US
This Viewpoint discusses the challenges of implementing “most-favored-nation,” or international reference, pricing for prescription drugs in the US.
Authors
- Thomas J. Hwang (ORCID: https://orcid.org/0000-0003-0717-1497)
- Luca Maini (ORCID: https://orcid.org/0000-0002-8125-0831)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Dana-Farber Brigham Cancer Center (US)
- Mass General Brigham (US)
Publication Details
- Journal
- JAMA
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1001/jama.2025.9398
- Citations
- 1
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 3.13